m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00720)
Name
BAY 1082439
Status
Phase 1
Structure
Formula
C25H30N6O5
InChI
1S/C25H30N6O5/c1-16-18(4-3-7-26-16)24(33)29-25-28-21-19(23-27-8-9-31(23)25)5-6-20(22(21)34-2)36-15-17(32)14-30-10-12-35-13-11-30/h3-7,17,27,32H,8-15H2,1-2H3/t17-/m0/s1
InChIKey
QJTLLKKDFGPDPF-KRWDZBQOSA-N
PubChem CID
136336430
TTD Drug ID
D0KJ2J
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
PI3-kinase beta (PIK3CB)
Methyltransferase-like 13 (METTL13)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The Methyltransferase-like 13 (METTL13) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase beta (PIK3CB) is a therapeutic target for BAY 1082439. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of BAY 1082439 through regulating the expression of PI3-kinase beta (PIK3CB). [1], [2]
References
Ref 1 N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020 Dec;69(12):2180-2192. doi: 10.1136/gutjnl-2019-320179. Epub 2020 Apr 20.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).